1. Vericiguat attenuates doxorubicin-induced cardiotoxicity through the PRKG1/PINK1/STING axis.
- Author
-
Zeng, Xianghui, Zhang, Hao, Xu, Tianyu, Mei, Xiyuan, Wang, Xiao, Yang, Qiling, Luo, Zhen, Zeng, Qingchun, Xu, Dingli, and Ren, Hao
- Abstract
Doxorubicin (DOX) is restricted due to its severe cardiotoxicity. There is still a lack of viable and effective drugs to prevent or treat DOX-induced cardiotoxicity(DIC). Vericiguat is widely used to treat heart failure with reduced ejection fraction. However, it is not clear whether vericiguat can improve DIC. In the present study, we constructed a DIC model using mice and neonatal rat cardiomyocytes and found that vericiguat ameliorated DOX-induced cardiac insufficiency in mice, restored DOX-induced mitochondrial dysfunction in neonatal rat cardiomyocytes, and inhibited the expression of inflammatory factors. Further studies showed that vericiguat improved mitochondrial dysfunction and reduced mtDNA leakage into the cytoplasm by up-regulating PRKG1, which activated PINK1 and then inhibited the STING/IRF3 pathway to alleviate DIC. These findings demonstrate for the first time that vericiguat has therapeutic potential for the treatment of DIC. The model illustrated that DOX inhibited PRKG1, PINK1 and PARKIN expression in the heart and activated STING/INF3 signaling pathway, leading to myocardial inflammation and cardiac dysfunction. Vericiguat alleviated myocardial inflammation and cardiac dysfunction by activating PRKG1, promoting PINK1 and PARKIN expression, inhibiting STING/INF3 signaling pathway, and improving mitochondrial function [Display omitted]. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF